Temab-A
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
- NCT05029882 ↗
- Active, not recruiting
- AbbVie
- Deep
We haven't built an HCP commentary report on Temab-A (ABBV-400, Trifluridine/Tipiracil and 1 more in Non-Small Cell Lung Cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on Temab-A so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 54 | |
| Bluesky threads | 11 | |
| YouTube | 4 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1 First in Human Study Evaluating Safety, Pharmacokinetics and Efficacy of ABBV-400 as Monotherapy and in Combination With Bevacizumab in Adult Subjects With Advanced Solid Tumors
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer; Advanced Solid Tumors; Gastroesophageal Adenocarcinoma; Colorectal Cancer
- Interventions
- ABBV-400; Trifluridine/Tipiracil; Bevacizumab
- Arms
- Part 1 (Monotherapy Dose Escalation) · Experimental
- Part 2i (wtEGFR Non-Small Cell Lung Cancer [NSCLC]) · Experimental
- Part 2ii (mutEGFR NSCLC) · Experimental
- Part 2iii (Squamous NSCLC) · Experimental
- Part 3 (Gastroesophageal Adenocarcinoma/Gastroesophagel Junct · Experimental
- Part 4 (Colorectal Cancer) · Experimental
- Part 5 (MET Amplification) · Experimental
- Part 6 (MET Mutation) · Experimental
- Part 7a (Combination Dose Escalation) · Experimental
- Part 7bi (Combination Dose Optimization Low Dose) · Experimental
- Part 7bii (Combination Dose Optimization High Dose) · Experimental
- Part 7biii (Combination Comparator) · Experimental
- Enrollment
- 520
- Primary outcomes
- Objective Response Rate (ORR)
- Sponsor
- AbbVie
- Start
- Oct 13, 2021
- Primary completion
- Nov 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05029882 · updated Oct 29, 2025
Publications
linked from the registry- Sharma MR, Powderly J, Kuboki Y, Strickler JH, Perets R, Cohen JE, Raimbourg J, Nakajima TE, Yamamoto N, Cruz-Correa M, O'Neil B, Ghiringhelli F, Raghav K, Cecchini M, Bar J, Hunter Z, Burns M, Blaney M, Morrison-Thiele G, Aristide MN, Freise KJ, Li R, Li M, Vasilopoulos A, Biesdorf C, Sommerhalder D. Phase I Study of Telisotuzumab Adizutecan (Temab-A, ABBV-400), a Novel c-Met Antibody-Drug Conjugate, in Patients With Late-Line Colorectal Cancer and Advanced Solid Tumors. J Clin Oncol. 2026 Jul 10;44(20):1876-1888. doi: 10.1200/JCO-25-01525. Epub 2026 May 1. PubMed 42066233